PFIRRMANN, M., R. E. CLARK, W. PREJZNER, M. LAUSEKER, M. BACCARANI, S. SAUSSELE, F. GUILHOT, S. HEIBL, R. HEHLMANN, E. FABER, A. TURKINA, G. OSSENKOPPELE, M. HOGLUND, A. ZARITSKEY, L. GRISKEVICIUS, U. OLSSON-STROMBERG, H. EVERAUS, P. KOSKENVESA, B. LABAR, T. SACHA, Daniela ŽÁČKOVÁ, F. CERVANTES, A. COLITA, I. ZUPAN, A. BOGDANOVIC, F. CASTAGNETTI, J. GUILHOT, J. HASFORD, A. HOCHHAUS and V. S. HOFFMANN. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia. London: Nature Publishing Group, 2020, vol. 34, No 8, p. 2138-2149. ISSN 0887-6924. Available from: https://dx.doi.org/10.1038/s41375-020-0931-9.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia
Authors PFIRRMANN, M. (276 Germany, guarantor), R. E. CLARK (826 United Kingdom of Great Britain and Northern Ireland), W. PREJZNER (616 Poland), M. LAUSEKER (276 Germany), M. BACCARANI (380 Italy), S. SAUSSELE (276 Germany), F. GUILHOT (250 France), S. HEIBL (40 Austria), R. HEHLMANN (276 Germany), E. FABER (203 Czech Republic), A. TURKINA (643 Russian Federation), G. OSSENKOPPELE (528 Netherlands), M. HOGLUND (752 Sweden), A. ZARITSKEY (643 Russian Federation), L. GRISKEVICIUS (440 Lithuania), U. OLSSON-STROMBERG (752 Sweden), H. EVERAUS (233 Estonia), P. KOSKENVESA (246 Finland), B. LABAR (191 Croatia), T. SACHA (616 Poland), Daniela ŽÁČKOVÁ (203 Czech Republic, belonging to the institution), F. CERVANTES (724 Spain), A. COLITA (642 Romania), I. ZUPAN (705 Slovenia), A. BOGDANOVIC (688 Serbia), F. CASTAGNETTI (380 Italy), J. GUILHOT (250 France), J. HASFORD (276 Germany), A. HOCHHAUS (276 Germany) and V. S. HOFFMANN (276 Germany).
Edition Leukemia, London, Nature Publishing Group, 2020, 0887-6924.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30205 Hematology
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 11.528
RIV identification code RIV/00216224:14110/20:00116177
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1038/s41375-020-0931-9
UT WoS 000544139100003
Keywords in English PROGNOSTIC DISCRIMINATION; IMATINIB TREATMENT; CML; VALIDATION; BOSUTINIB; DASATINIB; FRONTLINE; MODELS
Tags 14110212, rivok
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 29/10/2020 13:37.
Abstract
Prognostic scores support clinicians in selecting risk-adjusted treatments and in comparatively assessing different results. For patients with chronic-phase chronic myeloid leukemia (CML), four baseline prognostic scores are commonly used. Our aim was to compare the prognostic performance of the scores and to arrive at an evidence-based score recommendation. In 2949 patients not involved in any score development, higher hazard ratios and concordance indices in any comparison demonstrated the best discrimination of long-term survival with the ELTS score. In a second step, of 5154 patients analyzed to investigate risk group classification differences, 23% (n = 1197) were allocated to high-risk by the Sokal score. Of the 1197 Sokal high-risk patients, 56% were non-high-risk according to the ELTS score and had a significantly more favorable long-term survival prognosis than the 526 high-risk patients according to both scores. The Sokal score identified too many patients as high-risk and relatively few (40%) as low-risk (versus 60% with the ELTS score). Inappropriate risk classification jeopardizes optimal treatment selection. The ELTS score outperformed the Sokal score, the Euro, and the EUTOS score regarding risk group discrimination. The recent recommendation of the European LeukemiaNet for preferred use of the ELTS score was supported with significant statistical evidence.
PrintDisplayed: 7/6/2024 22:52